Novozymes South Asia Private Limited, a active private limited company, was established on 04 August 1998 in Bangalore, Karnataka, India. Engaging in industrial enzymes & biochemicals within the manufacturing sector, it holds CIN: U24299KA1998PTC024038. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹125.00 Cr and a paid-up capital of ₹113.92 Cr.
Formerly known as Novo Nordisk Enzymes Private Limited. It upholds a compliant status. Employing 542 professional, Its leadership includes Mikkel Viltoft (Director), Manish Kumar Mittal (Whole-Time Director), Krishnamohan Puvvada (Whole-Time Director). Past directors included Mikkel Viltoft, Uno Bonde Steffensen, Kristian Merser. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Plot No.32, 47-50 Epip Area, Whitefield, Bangalore, Karnataka, 560066.
U24299KA1998PTC024038
024038
04 August 1998
₹125.00 Cr
₹113.92 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Novozymes South Asia Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mikkel Viltoft | Director | 09 Sep 2009 | Current |
| Manish Kumar Mittal | Whole-Time Director | 01 Aug 2016 | Current |
| Krishnamohan Puvvada | Whole-Time Director | 26 Aug 2019 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 30 Sep 2009 | Past |
| Pramod Abcsdd | Director | 28 Aug 2014 | Past |
| Pramod Abcsdd | Director | 09 Sep 2009 | Past |
| Pramod Abcsdd | Managing Director | 27 Aug 2019 | Past |
| Pramod Abcsdd | Director | 26 Sep 2017 | Past |
| Pramod Abcsdd | Director | 12 Jun 2019 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Novozymes South Asia Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.15% increase. The company also saw a substantial improvement in profitability, with a 26.51% increase in profit. The company's net worth Soared by an impressive increase of 11.21%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Novozymes South Asia had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Novozymes South Asia has a workforce of 542 employees as of Oct 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Novozymes South Asia, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Novozymes South Asia's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Novozymes South Asia Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Novozymes South Asia Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was recorded as a recent event.
Progress on Krishnamohan Puvvada was appointed as a Whole-time director was appointed as a Whole-time director on 26 Aug 2019 & has been associated with this company since 6 years 3 months . was documented.
Sumedha Gajanan Hegde was appointed as a Company Secretary was appointed as a Company Secretary on 03 Apr 2018 & has been associated with this company since 7 years 7 months . was recorded as a recent event.
Manish Kumar Mittal was appointed as a Whole-time director was appointed as a Whole-time director on 01 Aug 2016 & has been associated with this company since 9 years 4 months . was recorded as a recent event.
Progress on Mikkel Viltoft was appointed as a Director was appointed as a Director on 09 Sep 2009 & has been associated with this company since 16 years 2 months . was documented.
The CIN of Novozymes South Asia Private Limited is U24299KA1998PTC024038.
Novozymes South Asia Private Limited is headquartered at Plot No.32, 47-50 Epip Area, Whitefield, Bangalore, Karnataka, 560066.
Novozymes South Asia Private Limited was incorporated on 04 August 1998.
The current directors of Novozymes South Asia Private Limited are
The primary industry of Novozymes South Asia Private Limited is Manufacturing.
Novozymes South Asia Private Limited is unlisted.
The authorized capital of Novozymes South Asia Private Limited is ₹125.00 Cr, and the paid-up capital is ₹113.92 Cr.
The compliance status of Novozymes South Asia Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX